Arthneeti

Unichem Laboratories Q2 FY27 Share Price & Earnings Call Analysis

₹498.75+0.33% today
Market cap
₹3,503 Cr
P/E
29.48
ROE
3.17%
PEG
0.84
Price to sales
1.48
Debt to equity
0.18
52W high / low
₹651 / ₹284
Sales growth (5Y)
12.26%
EBITDA margin
10.00%
Net profit margin
3.72%
Promoter holding
70.22%
Sales (last year)
₹2,369 Cr

Unichem Laboratories Ltd is involved in pharmaceuticals in Generics, APIs and Contract Manufacturing (CMO) areas.[1]

Guidance scorecard · Q2 FY27 call

What Unichem Laboratories's management guided
and where it ranks in Pharmaceuticals & Biotechnology

Revenue10–20%MarginsUp 0–2%CapexPlannedFundraisingWhat management saidOrder bookWhat management said

RevenueQ3 FY17 call

10–20%
  • For FY2018, Unichem expects growth better than the market average, aiming to outpace overall industry growth.
  • Despite demonetization impacts in November-December 2016 causing some revenue loss (~7.5%), January 2017 showed a positive traction, indicating recovery.
  • Unichem aims for a double-digit growth rate on a year-to-date basis for FY2017 and anticipates continuing this momentum into FY2018.
  • Domestic chronic segment, constituting about 62% of revenue, is showing better traction than acute segments.
  • Pillar brands demonstrate positive growth trends, supporting overall revenue increases.

2 more points from Unichem Laboratories's call on revenue

Create a free account to keep reading this call

Full Q3 FY17 analysis

MarginsQ3 FY17 call

Up 0–2%

See what Unichem Laboratories said on margins — free account, 30 seconds.

Full Q3 FY17 analysis

CapexQ3 FY17 call

Planned
  • The Goa manufacturing facility has been expanded; some minor bottlenecks and teething issues are being overcome with expected ramp-up to full rated capacity in the coming months.
  • Certain additional capital expenditure related to warehousing is pending; this may be done either within the current year or the next year.
  • Deferred tax provisioning related to capital expenditure is being monitored, with some room for adjustments depending on actual capitalization timelines.

2 more points from Unichem Laboratories's call on capex

Create a free account to keep reading this call

Full Q3 FY17 analysis

FundraisingQ3 FY17 call

See what Unichem Laboratories said on fundraising — free account, 30 seconds.

Full Q3 FY17 analysis

Order bookQ3 FY17 call

  • Unichem currently has around 17 pending ANDA (Abbreviated New Drug Applications) files in the US market.
  • These pending filings cover products identified earlier, mostly normal generics with existing competition (20-30 approvals already).
  • Market size per product is roughly USD 20 to 30 million at the manufacturing level, aggregating to around half a billion USD for all 17 products.
  • Out of these, about 15 products have had a soft launch, with one launched fully in Q3.

2 more points from Unichem Laboratories's call on the order book

Create a free account to keep reading this call

Full Q3 FY17 analysis
Full Pharmaceuticals & Biotechnology ranking

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Unichem Laboratories rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Unichem Laboratories latest results (Sep 2026)

Revenue

₹640 Cr

+11% YoY

Net profit

₹22 Cr

Operating margin

12%

EPS

₹3.16

What management said on the call →

Unichem Laboratories shareholding (Sep 2026)

Promoters

70.22%

unchanged QoQ

FIIs

2.70%

+1.80 pp QoQ

DIIs

9.40%

−1.06 pp QoQ

Public

17.67%

−0.74 pp QoQ

Full shareholding pattern →Dividend history →

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹3,041 Cr33.1
240%+Up 2%+₹492 Cr19.6
340%+Up 0–2%₹234 Cr17.8
440%+Flat₹18,347 Cr—
540%+Flat₹8,432 Cr32.4
640%+Flat₹4,295 Cr—

Sign up free to see every company in the sector ranking and track Unichem Laboratories.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Unichem Laboratories

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Unichem Laboratories

Shareholding breakup across reporting periods.

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters +70.22%70.22%70.22%70.22%70.22%70.22%70.22%70.22%70.22%70.22%70.22%70.22%
FIIs +0.84%0.90%0.89%0.94%1.05%0.98%0.98%0.99%0.99%1.00%0.90%2.70%
DIIs +10.46%11.26%11.57%11.65%11.63%11.32%10.92%10.74%10.73%10.63%10.46%9.40%
Public +18.47%17.63%17.32%17.17%17.11%17.47%17.88%18.04%18.05%18.14%18.41%17.67%
No. of Shareholders20,87721,17120,62120,37421,47221,62123,01023,57723,26723,38625,34726,164

Financials of Unichem Laboratories

Quarterly Results

Quarter-by-quarter operating performance

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales +416466432483507533587527579521575633640
YoY Sales growth+26%+54%+7%+14%+22%+14%+36%+9%+14%-2%-2%+20%+11%
Expenses +407435406443452448503504513476527563566
Operating Profit9312540558684226645487074
OPM %2.1%7%6%8%11%16%14%4.3%11%9%8%11%12%
Other Income +679-119491497-372871116-9
Interest7654575787978
Depreciation29322732323130323131313030
Profit before tax-2273-1268276258-9-11293194927
Tax %12%-0%3%74%9%6%8%16%10%10%42%15%19%
Net Profit +-2473-1292255853-10-12264114122
EPS in Rs-3.4810.40-18.370.293.508.227.52-1.49-1.6937.541.555.893.16

Financials of Unichem Laboratories

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +1,2021,3336988151,1801,1041,2351,2701,3431,7852,1112,2022,369
Sales growth+6%+11%-48%+17%+45%-6%+12%+3%+6%+33%+18%+4%+6%
Expenses +1,1001,1697389421,2541,1531,1441,1981,3891,6981,8462,0132,132
Operating Profit101164-41-128-74-499172-4687265189237
OPM %8%12%-6%-16%-6%-4.5%7%6%-3.4%4.9%13%9%10%
Other Income +20151842,73591915047-0-2635260305
Interest333888561723213231
Depreciation4139445167828491113123125125122
Profit before tax77137972,548-58-485122-176-85155292389
Tax %3%21%-12%0%-59%25%33%-50%15%10%11%14%
Net Profit +751081092,545-24-603433-202-94138253339
EPS in Rs8.3111.9011.96361.82-3.38-8.554.874.70-28.72-13.3219.5335.9148.14
Dividend Payout %24%17%25%1%-118%-47%82%85%-14%0%0%0%

Financials of Unichem Laboratories

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital18181814141414141414141414
Reserves8499361,0452,6662,6062,5172,5432,6042,4212,4242,4372,7032,767
Borrowings +223698151200206119349314248460500498
Other Liabilities +264283359359323407436351444589659489628
Total Liabilities1,1531,2741,5213,1903,1423,1453,1123,3193,1933,2753,5693,7073,908
Fixed Assets +4164034915788108708849901,2571,2521,3001,2131,170
CWIP1232372502389233056849414712331100126
Investments41141490192655039226421000
Other Assets +5746207661,4731,3131,3951,2691,5711,7871,8982,2392,3942,612
Total Assets1,1531,2741,5213,1903,1423,1453,1123,3193,1933,2753,5693,7073,908

Financials of Unichem Laboratories

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +7811268-112-3282033-260-8514-74
Cash from Investing Activity +-52-85-1321,648-286-36-6610024163-242194
Cash from Financing Activity +-51-3359-881-2-62-121191-81-1061842
Net Cash Flow-25-7-4655-616-78-1543275-29-65200
Free Cash Flow4-28-79-271-519-360-254-386-1230-142163
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit95%87%-237%89%424%-49%52%-350%160%23%4%6%

Financials of Unichem Laboratories

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days586016512413512974142160131135137
Inventory Days171184397278278374518527414365418349
Days Payable114131297230182236202161193174164128
Cash Conversion Cycle116113265172231267390508382322389358
Working Capital Days8890174133165154163207207173159169
ROCE %9%15%9%128%-2%-2%2%1%-5%-0%6%4%

Guidance history

How Unichem Laboratories's guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q3 FY17 call →10–20%Up 0–2%Planned——
Q2 FY17 call →10–20%Up 0–2%Planned——
Q1 FY17 call →20–40%Up 0–2%Planned——
Q4 FY16 call →10–20%Up 0–2%Planned——

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

32out of 100

Momentum score · price trend

32 out of 100 — Cooling

Over the past year its share price has done worse than most of the stocks we track.

PeriodShare price changeBetter than … of 1,937 stocks
Last 12 months+6.2%60%
Last 6 months+33.9%80%
Last 3 months−7.7%38%

The price is 44.6% below its all-time high of ₹900.55 (8 Nov 2024). Stocks more than 20% below their peak have their score halved, so 63 became 32.

How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,937 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Unichem Laboratories: 0.4 × 60 + 0.4 × 80 + 0.2 × 38 = 63, halved to 32 because the price is more than 20% below its all-time high.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 13 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Unichem Laboratories: frequently asked questions

What is Unichem Laboratories share price today?

Unichem Laboratories last traded at ₹498.75, with a market capitalisation of ₹3,503 Cr and a P/E ratio of 29.5.

What were Unichem Laboratories's latest quarterly results?

For the quarter ended Sep 2026, Unichem Laboratories reported revenue of ₹640 Cr (+11% year on year) and net profit of ₹22 Cr, with an operating margin of 12%.

Is Unichem Laboratories's profit growing?

Net profit was ₹22 Cr in Sep 2026 against ₹-12 Cr in Sep 2025.

What is Unichem Laboratories's EPS?

Unichem Laboratories's earnings per share for the quarter ended Sep 2026 was ₹3.16.

What is the promoter holding in Unichem Laboratories?

Promoters held 70.22% of Unichem Laboratories in Sep 2026 (unchanged versus Jun 2026).

How much do FIIs and DIIs hold in Unichem Laboratories?

In Sep 2026, foreign institutional investors held 2.70% and domestic institutions (including mutual funds) held 9.40% of Unichem Laboratories.

What is Unichem Laboratories's ROE and ROCE?

Unichem Laboratories's return on equity is 3.17% and its return on capital employed is 4.13%.

Does Unichem Laboratories pay a dividend?

Unichem Laboratories's dividend yield is 0% at the current price; see the Unichem Laboratories dividends page for past payouts.

Which sector does Unichem Laboratories belong to?

Unichem Laboratories is in the Pharmaceuticals & Biotechnology sector. Its peer comparison and sector ranking are on this page.

What did Unichem Laboratories's management say on the latest earnings call?

Arthneeti's analysis of the Q2 FY27 earnings call covers revenue, margins, capex and fundraising guidance from Unichem Laboratories's management.

How does Arthneeti AI analyse Unichem Laboratories?

Arthneeti reads Unichem Laboratories's earnings call transcripts and filings and scores revenue growth, margins, capex and fundraising, then ranks the company against its sector.

Continue your research

What Unichem Laboratories's management said in earlier quarters

Earlier calls (3)

Others in Pharmaceuticals & Biotechnology this season

  • Natural Capsules (Q2 FY27)

    11.67% increase. Key results statement takeaways from Natural Capsules Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Sotac Pharmaceuticals (Q2 FY27)

    7,654.95 lakhs; Operating margin ≈ 10.68% for HY Sep 2026 . Key results statement takeaways from Sotac Pharmaceuticals Ltd's Q2 FY27 results statement — and how

  • Bio Medica Lab (Q2 FY27)

    EBITDA for the quarter:** ₹510 lakhs, up 25% year-on-year (YoY). Key results statement takeaways from Bio Medica Laboratories Ltd's Q2 FY27 results statement —

  • Syncom Formulations (India) (Q2 FY27)

    Quarterly Revenue (Q2 FY 2026-27 ended 30/09/2026):** ₹14,821.08 lakhs (Unaudited) . Key results statement takeaways from Syncom Formulations (India) Ltd's Q2 F